# PODN

## Overview
Podocan (PODN) is a gene that encodes the protein podocan, a member of the small leucine-rich proteoglycan (SLRP) family. This protein is characterized by its leucine-rich repeat (LRR) domains, which are essential for its structural integrity and its role in protein-protein interactions. Podocan is involved in various cellular processes, including the regulation of cell proliferation, migration, and differentiation, particularly in vascular biology and muscle development. It acts as a negative regulator of smooth muscle cell migration and proliferation, influencing the formation of neointima and modulating the Wnt-TCF signaling pathway (Liu2019Podocan; Hutter2013Novel). Additionally, podocan interacts with extracellular matrix components, such as type 1 collagen, and plays a role in myogenic differentiation by enhancing Wnt/β-catenin signaling (ShimizuHirota2004Functional; Li2019Podocan). The clinical significance of PODN is highlighted by its differential expression in diseases like osteosarcoma and its potential as a prognostic biomarker (Yao2021PODN).

## Structure
Podocan (PODN) is a member of the small leucine-rich proteoglycan (SLRP) family, characterized by leucine-rich repeat (LRR) domains. These LRR domains are crucial for the protein's structural stability and its ability to engage in protein-protein interactions. The LRR domains in podocan are flanked by cysteine clusters, which contribute to the formation of disulfide bonds, enhancing the stability of the domain (Matsushima2021Sequence). Podocan contains seven tandem repeats of the STT super motif, a combination of Bacterial and Typical LRRs, which provides insights into its molecular structure (Matsushima2021Sequence).

Podocan does not have a C-terminal capping motif, which is a feature present in some other LRR proteins (Matsushima2021Sequence). It also lacks glycosaminoglycan (GAG) side chains, a common feature in many proteoglycans (Matsushima2021Sequence). The protein may undergo post-translational modifications such as glycosylation, although specific details on these modifications are not extensively documented in the provided context. The absence of detailed information on the secondary, tertiary, and quaternary structures of podocan limits a comprehensive understanding of its full molecular architecture.

## Function
Podocan (PODN) is a small leucine-rich repeat protein (SLRP) that plays a significant role in regulating cell proliferation, migration, and differentiation. In healthy human cells, podocan acts as a negative regulator of smooth muscle cell (SMC) migration and proliferation, which are critical processes in vascular biology. It is involved in the formation of neointima, a thickened layer of tissue that can develop in blood vessels after injury, by modulating the Wnt-TCF signaling pathway. Podocan deficiency leads to increased SMC proliferation and migration, while its overexpression suppresses these processes, indicating its role in maintaining vascular homeostasis (Hutter2013Novel).

Podocan also influences myogenic differentiation by enhancing Wnt/β-catenin signaling. In C2C12 myoblasts, podocan promotes differentiation by increasing nuclear β-catenin levels, which is crucial for muscle development and regeneration (Liu2019Podocan). Additionally, podocan is involved in extracellular matrix interactions, binding to type 1 collagen, and influencing cell growth and migration through its effects on the cell cycle, particularly by modulating the expression of cell cycle-related proteins such as p21 and cdk2 (Sun2016MiR; ShimizuHirota2004Functional).

## Clinical Significance
Alterations in the expression of the PODN gene, which encodes the protein podocan, have been implicated in various diseases, particularly in cancer and cardiovascular conditions. In osteosarcoma, a common bone malignancy in children and adolescents, PODN is significantly differentially expressed between normal and cancerous tissues. High PODN expression is associated with poor prognosis, affecting overall survival and disease-free survival rates. This suggests that PODN could serve as a prognostic biomarker in osteosarcoma, with its expression levels potentially influencing cancer progression through interactions with immune cells and extracellular matrix components (Yao2021PODN).

In the context of vascular diseases, podocan acts as a negative regulator of smooth muscle cell (SMC) migration and proliferation. Its expression is increased in sclerotic glomerular lesions and is present in normal heart and kidney tissues. Podocan deficiency leads to increased arterial lesion formation and SMC proliferation, indicating its role in modulating arterial repair and SMC behavior. This regulatory function is linked to the Wnt-TCF pathway, which is upregulated in podocan-deficient SMCs, suggesting a mechanism through which podocan influences vascular conditions such as atherosclerosis (Hutter2013Novel).

## Interactions
Podocan (PODN) is known to interact with several proteins, influencing various cellular processes. It binds to type 1 collagen, a characteristic feature of small leucine-rich repeat (SLR) proteins, suggesting a role in extracellular matrix interactions (ShimizuHirota2004Functional). Podocan also interacts with components of the Wnt/β-catenin signaling pathway, particularly Wnt4. This interaction has been demonstrated through co-immunoprecipitation experiments, where podocan was shown to form complexes with Wnt4, affecting the differentiation of bovine muscle-derived satellite cells (Li2019Podocan). The interaction with Wnt4 suggests that podocan may regulate the Wnt/β-catenin signaling pathway, which is crucial for muscle cell differentiation (Li2019Podocan).

In the context of vascular biology, podocan has been shown to negatively regulate smooth muscle cell (SMC) proliferation and migration. This regulatory effect is significant in the formation of neointima following arterial injury, where podocan-deficient mice exhibited increased SMC density and larger neointima areas compared to wild-type mice (Hutter2013Novel). These interactions highlight podocan's role in modulating cellular behavior and its potential impact on tissue repair and fibrosis.


## References


[1. (ShimizuHirota2004Functional) Ryoko Shimizu-Hirota, Hiroyuki Sasamura, Mari Kuroda, Emi Kobayashi, and Takao Saruta. Functional characterization of podocan, a member of a new class in the small leucine‐rich repeat protein family. FEBS Letters, 563(1–3):69–74, March 2004. URL: http://dx.doi.org/10.1016/s0014-5793(04)00250-9, doi:10.1016/s0014-5793(04)00250-9. This article has 42 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/s0014-5793(04)00250-9)

[2. (Sun2016MiR) Yi Sun, De-Yi Luo, Yu-Chun Zhu, Liang Zhou, Tong-Xin Yang, Cai Tang, Hong Shen, and Kun-Jie Wang. Mir 3180-5p promotes proliferation in human bladder smooth muscle cell by targeting podn under hydrodynamic pressure. Scientific Reports, September 2016. URL: http://dx.doi.org/10.1038/srep33042, doi:10.1038/srep33042. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/srep33042)

[3. (Li2019Podocan) Shuang Li, Dan Liu, Yuying Fu, Chunyu Zhang, Huili Tong, Shufeng Li, and Yunqin Yan. Podocan promotes differentiation of bovine skeletal muscle satellite cells by regulating the wnt4-β-catenin signaling pathway. Frontiers in Physiology, August 2019. URL: http://dx.doi.org/10.3389/fphys.2019.01010, doi:10.3389/fphys.2019.01010. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fphys.2019.01010)

[4. (Liu2019Podocan) Dan Liu, Shuang Li, Yafeng Cui, Huili Tong, Shufeng Li, and Yunqin Yan. Podocan affects c2c12 myogenic differentiation by enhancing wnt/β‐catenin signaling. Journal of Cellular Physiology, 234(7):11130–11139, January 2019. URL: http://dx.doi.org/10.1002/jcp.27763, doi:10.1002/jcp.27763. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/jcp.27763)

[5. (Yao2021PODN) Feng Yao, Zhao Feng Zhu, Jun Wen, Fu Yong Zhang, Zheng Zhang, Lun Qing Zhu, Guang Hao Su, Quan Wen Yuan, Yun Fang Zhen, and Xiao Dong Wang. Podn is a prognostic biomarker and correlated with immune infiltrates in osteosarcoma. Cancer Cell International, July 2021. URL: http://dx.doi.org/10.1186/s12935-021-02086-5, doi:10.1186/s12935-021-02086-5. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12935-021-02086-5)

[6. (Hutter2013Novel) Randolph Hutter, Li Huang, Walter S. Speidl, Chiara Giannarelli, Paul Trubin, Gerhard Bauriedel, Mary E. Klotman, Valentin Fuster, Juan J. Badimon, and Paul E. Klotman. Novel small leucine-rich repeat protein podocan is a negative regulator of migration and proliferation of smooth muscle cells, modulates neointima formation, and is expressed in human atheroma. Circulation, 128(22):2351–2363, November 2013. URL: http://dx.doi.org/10.1161/circulationaha.113.004634, doi:10.1161/circulationaha.113.004634. This article has 30 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1161/circulationaha.113.004634)

[7. (Matsushima2021Sequence) Norio Matsushima, Hiroki Miyashita, and Robert H. Kretsinger. Sequence features, structure, ligand interaction, and diseases in small leucine rich repeat proteoglycans. Journal of Cell Communication and Signaling, 15(4):519–531, April 2021. URL: http://dx.doi.org/10.1007/s12079-021-00616-4, doi:10.1007/s12079-021-00616-4. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s12079-021-00616-4)